Quince Therapeutics reports FY24 EPS ($1.31), one estimate ($1.17)

Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “Our Phase 3 pivotal NEAT clinical trial has exceeded 50% enrollment with 71 participants screened and 61 randomized. Recent and upcoming new site activations are expected to accelerate enrollment through our target completion date in the second quarter of 2025. Assuming target enrollment completion, topline results from the NEAT study are anticipated in the fourth quarter of 2025.”